<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632473</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01818; me14Fuhr</org_study_id>
    <nct_id>NCT03632473</nct_id>
  </id_info>
  <brief_title>Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis</brief_title>
  <acronym>SMSC</acronym>
  <official_title>Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis: Sub-study Within the Swiss Multiple Sclerosis Cohort (SMSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Utility of Multimodal Evoked potentials (mmEP) for monitoring disease course and prediction
      of progression at different stages of Multiple Sclerosis (MS) is investigated
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 12, 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>correlation of EP-sum-score (Î£-EP) and the Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>3 years</time_frame>
    <description>logistic regression model will be used to predict worsening in EDSS defined by a 1-point-change (0.5 if EDSS is 5.5 or higher) at year 3</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>clinically isolated syndrome (CIS)</arm_group_label>
    <description>Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.
Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>early relapsing-remitting late disease course (RRMS)</arm_group_label>
    <description>MS with relapsing-remitting early disease course (RRMS) &lt;/= 10 years, Expanded Disability Status Scale (EDSS) &lt;/=3.5
EDSS:
1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.
Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>late relapsing-remitting late disease course (RRMS)</arm_group_label>
    <description>MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive
EDSS:
4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.
Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>primary progressive disease course (PPMS)</arm_group_label>
    <description>MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive
EDSS:
6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.
Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multimodal evoked potentials (mmEP)</intervention_name>
    <description>combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)</description>
    <arm_group_label>clinically isolated syndrome (CIS)</arm_group_label>
    <arm_group_label>early relapsing-remitting late disease course (RRMS)</arm_group_label>
    <arm_group_label>late relapsing-remitting late disease course (RRMS)</arm_group_label>
    <arm_group_label>primary progressive disease course (PPMS)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MS patients participating in the Swiss Multiple Sclerosis Cohort Study (SMSC), regardless
        of MS-specific treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with a clinically isolated syndrome (CIS) or MS with a relapsing-remitting
             (RRMS) or a primary progressive disease course (PPMS):

          -  CIS: EDSS &lt;= 5.5 within six months of first clinical event

          -  early RRMS: EDSS: &lt;= 3.5 disease course of 5 up to 10 years

          -  late RRMS: EDSS: 2.0-5.5 inclusive disease course of 5 to 15 years

          -  PPMS: EDSS: 2.0-6.5 inclusive disease course up to 15 years

          -  participation in the Swiss Multiple Sclerosis Cohort Study (SMSC)

          -  mental ability to cooperate

          -  written informed consent

        Exclusion Criteria:

          -  alcohol or substance abuse

          -  progressive disease other than Multiple Sclerosis

          -  psychiatric disorder requiring a treatment by a psychiatrist

          -  patients with movable metal implants, e.g. pace-maker, stents, deep brain stimulators
             etc.;(patients with jaw- or bone-fixed metal implants can be included)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Fuhr, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Neurology, Hospital of the University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Fuhr, Prof.</last_name>
    <phone>+41 61 265 4166</phone>
    <email>peter.fuhr@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dep. of Neurology, Hospital of the University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Fuhr, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Ludwig Kappos, Prof. Dr. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Derfuss, Prof. Dr. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Till Sprenger, Prof. Dr. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Hardmeier, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Schlaeger, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Kuhle, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oezguer Yaldizli, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Schindler, PD Dr. phil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leticia Grize, Dr. phil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris- Katharina Penner, PD Dr. phil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Gobbi, PD Dr. med</last_name>
      <phone>0041 91 811 6921</phone>
      <email>claudio.gobbi@eoc.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multimodal Evoked potentials</keyword>
  <keyword>Visual evoked potentials</keyword>
  <keyword>Somato-sensory evoked potentials</keyword>
  <keyword>Motor evoked potentials</keyword>
  <keyword>Expanded Disability Status Scale (EDSS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

